Patents by Inventor Olivier Jolois

Olivier Jolois has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant alpha-hemolysin polypeptide of , having a deletion in the stem domain and heterologous sequences inserted
    Patent number: 8545853
    Abstract: It refers to a recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, comprising a deletion in the stem domain, wherein at least one heterologous sequence is inserted in a region selected from the group consisting of regions defined by amino acid position of 108 to 151, 1 to 5, 288 to 293, 43 to 48, 235 to 240, 92 to 97, 31 to 36,or 156 to 161 of SEQ ID NO: 1, with the proviso that, if the heterologous sequence contains five or more consecutive histidines the moiety of the heterologous sequence other than the moiety of five or more consecutive histidines has a minimum length of 11 amino acids; or a variant thereof comprising 1-50 amino acids added, substituted or deleted in SEQ ID NO. 1 and the activity to form oligomers and to bind to lipidic bilayers. It also provides a medicament and vaccine comprising said recombinant polypeptide.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: October 1, 2013
    Assignees: Universite de Liege, Centre d'Economie Rurale, Universite Libre de Bruxelles
    Inventors: Patrice Filee, Noureddine Rhazi, Moreno Galleni, Bernard Taminiau, Olivier Jolois, Alfred Collard, Alain Jacquet
  • RECOMBINANT ALPHA-HEMOLYSIN POLYPEPTIDE OF STAPHYLOCOCCUS AUREUS, HAVING A DELETION IN THE STEM DOMAIN AND HETEROLOGOUS SEQUENCES INSERTED
    Publication number: 20120014983
    Abstract: It refers to a recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, comprising a deletion in the stem domain, wherein at least one heterologous sequence is inserted in a region selected from the group consisting of regions defined by amino acid position of 108 to 151, 1 to 5, 288 to 293, 43 to 48, 235 to 240, 92 to 97, 31 to 36,or 156 to 161 of SEQ ID NO: 1, with the proviso that, if the heterologous sequence contains five or more consecutive histidines the moiety of the heterologous sequence other than the moiety of five or more consecutive histidines has a minimum length of 11 amino acids; or a variant thereof comprising 1-50 amino acids added, substituted or deleted in SEQ ID NO. 1 and the activity to form oligomers and to bind to lipidic bilayers. It also provides a medicament and vaccine comprising said recombinant polypeptide.
    Type: Application
    Filed: January 15, 2010
    Publication date: January 19, 2012
    Applicants: UNIVERSITE DE LIEGE, UNIVERSITE LIBRE DE BRUXELLES, CENTRE D'ECONOMIE RURALE
    Inventors: Patrice Filee, Noureddine Rhazi, Moreno Galleni, Bernard Taminiau, Olivier Jolois, Alfred Collard, Alain Jacquet